Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the molecular formula C₁₉H₁₀BrClFN₅O and a monoisotopic mass of approximately 456.97 Da. It features a pyrazolopyridazine core linked via a methylene bridge to a phenoxy group substituted with bromo and fluoro substituents, as well as a chlorobenzonitrile moiety. The structure is consistent with annulated pyrazole derivatives that have been studied for antiviral activity, particularly as inhibitors targeting the Gag–Pol polyprotein of HIV‑1. The compound has been referenced in structural studies (PDB ligand code: PZL), indicating its use in biochemical or biophysical research related to HIV‑1 enzyme inhibition[8][5]. There is no evidence it has reached clinical development or approval.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile.